CN102333773B - 盐皮质激素受体拮抗剂及使用方法 - Google Patents

盐皮质激素受体拮抗剂及使用方法 Download PDF

Info

Publication number
CN102333773B
CN102333773B CN201080009314.8A CN201080009314A CN102333773B CN 102333773 B CN102333773 B CN 102333773B CN 201080009314 A CN201080009314 A CN 201080009314A CN 102333773 B CN102333773 B CN 102333773B
Authority
CN
China
Prior art keywords
compound
solid
added
stirred
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080009314.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102333773A (zh
Inventor
D·A·科茨
K·加瓦蒂那纳斯
P·K·贾达夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102333773A publication Critical patent/CN102333773A/zh
Application granted granted Critical
Publication of CN102333773B publication Critical patent/CN102333773B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080009314.8A 2009-03-12 2010-03-04 盐皮质激素受体拮抗剂及使用方法 Expired - Fee Related CN102333773B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15957809P 2009-03-12 2009-03-12
US61/159,578 2009-03-12
PCT/US2010/026138 WO2010104721A1 (en) 2009-03-12 2010-03-04 Mineralocorticoid receptor antagonist and methods of use

Publications (2)

Publication Number Publication Date
CN102333773A CN102333773A (zh) 2012-01-25
CN102333773B true CN102333773B (zh) 2014-04-16

Family

ID=42139981

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080009314.8A Expired - Fee Related CN102333773B (zh) 2009-03-12 2010-03-04 盐皮质激素受体拮抗剂及使用方法

Country Status (12)

Country Link
US (1) US8658638B2 (cg-RX-API-DMAC7.html)
EP (1) EP2406252B1 (cg-RX-API-DMAC7.html)
JP (1) JP5570536B2 (cg-RX-API-DMAC7.html)
KR (1) KR101312179B1 (cg-RX-API-DMAC7.html)
CN (1) CN102333773B (cg-RX-API-DMAC7.html)
AU (1) AU2010222902B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1009257A2 (cg-RX-API-DMAC7.html)
CA (1) CA2751901C (cg-RX-API-DMAC7.html)
EA (1) EA019179B1 (cg-RX-API-DMAC7.html)
ES (1) ES2542001T3 (cg-RX-API-DMAC7.html)
MX (1) MX2011009506A (cg-RX-API-DMAC7.html)
WO (1) WO2010104721A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI431010B (zh) 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法
ME03316B (me) 2014-06-30 2019-10-20 Astrazeneca Ab Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
EP4118235B1 (en) 2020-03-11 2026-08-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
WO2005066161A1 (en) * 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI431010B (zh) * 2007-12-19 2014-03-21 Lilly Co Eli 礦皮質素受體拮抗劑及使用方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
CN1665780A (zh) * 2002-06-26 2005-09-07 伊莱利利公司 三环甾类激素核受体调节剂
WO2005066161A1 (en) * 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
CN1918151A (zh) * 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities;Richard J.Bastin,etc;《Organic Process Research and Development》;20001231(第4期);第427-435页 *
Salt selection for basic drugs;Philip L.Gould;《International Journal of Pharmaceutics》;19861231;第33卷;第201-217页 *

Also Published As

Publication number Publication date
CA2751901A1 (en) 2010-09-16
JP5570536B2 (ja) 2014-08-13
EA019179B1 (ru) 2014-01-30
EP2406252A1 (en) 2012-01-18
BRPI1009257A2 (pt) 2016-03-08
US20110312954A1 (en) 2011-12-22
ES2542001T3 (es) 2015-07-29
EA201171125A1 (ru) 2012-02-28
US8658638B2 (en) 2014-02-25
KR20110124305A (ko) 2011-11-16
CN102333773A (zh) 2012-01-25
KR101312179B1 (ko) 2013-09-26
AU2010222902A1 (en) 2011-08-11
CA2751901C (en) 2013-08-06
MX2011009506A (es) 2011-09-28
EP2406252B1 (en) 2015-05-20
WO2010104721A1 (en) 2010-09-16
AU2010222902B2 (en) 2013-04-18
JP2012520302A (ja) 2012-09-06

Similar Documents

Publication Publication Date Title
JP7746496B2 (ja) 選択的エストロゲン受容体分解剤
CN101903377B (zh) 6H-二苯并[b,e]氧杂环庚烷衍生的非类固醇矿皮质激素受体拮抗剂
CA3105491C (en) Selective estrogen receptor degraders
CN102333773A (zh) 盐皮质激素受体拮抗剂及使用方法
WO2016199943A1 (en) Heterocyclic compounds
EP2043646B1 (en) (E)-N-{3-(8-Chloro-11H-10-oxa-1-aza- dibenzo[a,d]cyclohepten-5-ylidene)-propyl]-phenyl} -methanesulfonamide as a GLUCOCORTICOID RECEPTOR MODULATOR AND METHODS OF USE
CA3208671C (en) Selective estrogen receptor degraders
TWI882609B (zh) 化合物的晶型及其製備方法和用途
EA049962B1 (ru) Новые соединения, применяемые в качестве ингибиторов поли(адф-рибоза)полимеразы (parp)
HK40041681B (en) Selective estrogen receptor degraders
HK40041681A (en) Selective estrogen receptor degraders

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140416

Termination date: 20190304

CF01 Termination of patent right due to non-payment of annual fee